Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD35 Antibody (CR1/802), Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2446190.2MG
Description
Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
CD35 Monoclonal antibody specifically detects CD35 in Human, Baboon, Monkey samples. It is validated for Flow Cytometry, Immunohistochemistry-Paraffin, Immunofluorescence.Specifications
CD35 | |
Monoclonal | |
0.2mg/mL | |
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 1 - 2 ug/ml | |
P17927 | |
CR1 | |
Recombinant human CR1 protein | |
0.2 mg | |
Primary | |
Recognizes a protein of 210-220kDa, which is identified as the complement receptor 1 (CR1)/CD35. This MAb does not block CR1 activity. It is highly specific to CR1 and shows no cross-reaction with CR2. The primary function of CR1 is to serve as the cellular receptor for C3b and C4b, the most important components of the complement system leading to clearance of foreign macromolecules. The Knops blood group system is a system of antigens located on this protein. Follicular dendritic cells (FDC) are restricted to the B-cell regions of secondary lymphoid follicles. They are CD21+/CD35+/CD1a-. This MAb labels follicular dendritic cells and follicular dendritic cell sarcoma. | |
Store at 4C. | |
IgG1 κ |
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence | |
CR1/802 | |
Unconjugated | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
complement component (3b/4b) receptor 1 (Knops blood group), KN | |
Mouse | |
Protein A or G purified | |
RUO | |
1378 | |
Human, Baboon, Monkey | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction